Saretius

Saretius is a specialist contract research organization (CRO) providing high-quality preclinical services to the pharmaceutical and biotechnology industries. Founded in 2008 and based in the United Kingdom, the company focuses on in vivo pharmacology, particularly in the areas of metabolic diseases, pain, inflammation, and central nervous system (CNS) disorders. Saretius offers a comprehensive suite of services including pharmacokinetic (PK) and pharmacodynamic (PD) relationship determination, biomarker development, and efficacy testing. In April 2025, Saretius was acquired by Transpharmation Ltd, a global leader in translational neuroscience, to enhance its portfolio of disease models and biomarker technologies. The company continues to operate as a subsidiary, leveraging its expertise in surgical models and metabolic phenotyping to support drug discovery from target validation to lead optimization.